Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma-Reference-Cited by-同舟云学术

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Published:2015-01-08 Issue:2 Volume:372 Page:142-152
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Stewart A. Keith,Rajkumar S. Vincent,Dimopoulos Meletios A.,Masszi Tamás,Špička Ivan,Oriol Albert,Hájek Roman,Rosiñol Laura,Siegel David S.,Mihaylov Georgi G.,Goranova-Marinova Vesselina,Rajnics Péter,Suvorov Aleksandr,Niesvizky Ruben,Jakubowiak Andrzej J.,San-Miguel Jesus F.,Ludwig Heinz,Wang Michael,Maisnar Vladimír,Minarik Jiri,Bensinger William I.,Mateos Maria-Victoria,Ben-Yehuda Dina,Kukreti Vishal,Zojwalla Naseem,Tonda Margaret E.,Yang Xinqun,Xing Biao,Moreau Philippe,Palumbo Antonio

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1411321

Cited by 1129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Visible light–driven organic synthesis under Rose Bengal photocatalysis;Visible Light-Driven Organic Synthesis;2025

2. Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States;Journal of Managed Care & Specialty Pharmacy;2024-09-09

3. Proceedings from the First Onco Summit: LATAM Chapter, 19–20 May 2023, Rio de Janeiro, Brazil;Cancers;2024-09-03

4. Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS;Frontiers in Pharmacology;2024-09-03

5. Proteasome and PARP1 dual-target inhibitor for multiple myeloma: Fluzoparib;Biochemistry and Biophysics Reports;2024-09